Melanoma antigens recognized by T cells and their use for immunotherapy
Experimental Dermatology · 2023
DOI: 10.1111/exd.14741 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Experimental Dermatology, 2023. Verfasst von Shigeki Ohta und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, School of Medicine, International University of Health and Welfare, Chiba, Japan. Hauptthemen laut MEDLINE: Melanoma, Cancer Vaccines. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development, Ministry of Education, Culture, Sports, Science and Technology.
Abstract (Originalsprache)
Melanoma has been a prototype for cancer immunology research, and the mechanisms of anti‐tumor T‐cell responses have been extensively investigated in patients treated with various immunotherapies. Individual differences in cancer‐immune status are defined mainly by cancer cell characteristics such as DNA mutations generating immunogenic neo‐antigens, and oncogene activation causing immunosuppression, but also by patients' genetic backgrounds such as HLA types and genetic polymorphisms of immune related molecules, and environmental and lifestyle factors such as UV rays, smoking, gut microbiota and concomitant medications; these factors have an influence on the efficacy of immunotherapy. Recent comparative studies on responders and non‐responders in immune‐checkpoint inhibitor therapy using various new technologies including multi‐omics analyses on genomic DNA, mRNA, metabolites and microbiota and single cell analyses of various immune cells have led to the advance of human tumor immunology and the development of new immunotherapy. Based on the new findings from these investigations, personalized cancer immunotherapies along with appropriate biomarkers and therapeutic targets are being developed for patients with melanoma. Here, we will discuss one of the essential subjects in tumor immunology: identification of immunogenic tumor antigens and their effective use in various immunotherapies including cancer vaccines and adoptive T‐cell therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, School of Medicine, International University of Health and Welfare, Chiba, Japan.
- Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan.
ORCID-Profile: Yutaka Kawakami
Förderung
- Japan Agency for Medical Research and Development
- Ministry of Education, Culture, Sports, Science and Technology
Zitieren
APA
Ohta, S., Misawa, A., Kyi-Tha-Thu, C., Matsumoto, N., Hirose, Y., & Kawakami, Y. (2023). Melanoma antigens recognized by T cells and their use for immunotherapy. Experimental Dermatology. https://doi.org/10.1111/exd.14741
Vancouver
Ohta S, Misawa A, Kyi-Tha-Thu C, Matsumoto N, Hirose Y, Kawakami Y. Melanoma antigens recognized by T cells and their use for immunotherapy. Experimental Dermatology. 2023. doi:10.1111/exd.14741
BibTeX
@article{Ohta2023,
author = {Ohta, Shigeki and Misawa, Aya and Kyi-Tha-Thu, Chaw and Matsumoto, Naomi and Hirose, Yoshie and Kawakami, Yutaka},
title = {Melanoma antigens recognized by T cells and their use for immunotherapy},
journal = {Experimental Dermatology},
year = {2023},
doi = {10.1111/exd.14741}
}
EUVIMED